Relapsed/Refractory Follicular Lymphoma Study
Phase: 1b/3
Status: Ongoing
About
A Phase 1b/3 Study in Subjects With Relapsed/Refractory Follicular Lymphoma.
Details
Symphony-1: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker
adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab
in subjects with relapsed/refractory follicular lymphoma.
Sponsor: Epizyme, Inc
NCT04224493